导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.58% | 975/4773 |
| 近一周 | -1.91% | 869/5462 |
| 近一月 | -1.68% | 999/5421 |
| 近一季 | 1.56% | 527/5209 |
| 近半年 | -0.37% | 1283/4920 |
| 近一年 | 9.64% | 1073/4366 |
| 近两年 | 50.29% | 1458/2954 |
| 近三年 | 24.16% | 1316/2253 |
| 成立以来 | 94.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.13% 1046/4961 |
0.45% 3179/5312 |
- - |
- - |
| 2025 | 16.39% 2457/4813 |
1.62% 1583/3635 |
0.89% 2539/4076 |
10.46% 3287/4524 |
2.78% 849/4813 |
| 2024 | 6.67% 1737/3463 |
0.25% 1013/2808 |
-3.50% 1383/3014 |
10.34% 2631/3129 |
-0.06% 1305/3463 |
| 2023 | -6.05% 807/2656 |
8.22% 481/2280 |
-1.81% 529/2385 |
-5.81% 1381/2515 |
-6.12% 1633/2655 |
| 2022 | -19.29% 832/2207 |
-14.54% 964/1919 |
6.46% 695/2016 |
-11.00% 485/2113 |
-0.34% 1596/2208 |
| 2021 | 12.76% 376/1822 |
-4.08% 847/1255 |
9.92% 510/1330 |
8.66% 155/1466 |
-1.57% 1374/1822 |
| 2020 | 39.31% 337/1250 |
-3.79% 322/1028 |
24.58% 169/1067 |
11.69% 430/1164 |
4.06% 875/1184 |
| 2019 | - - |
- - |
- - |
- - |
11.24% 72/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万菱信中证500指数增强C VS. 长安沪深300非周期A(740101) |